Management of Congenital Aniridia-Associated Keratopathy: Long-Term Outcomes from a Tertiary Referral Center.
To report the outcomes of medical and surgical management for congenital aniridia-associated keratopathy (AAK) over a long follow-up period. Retrospective, comparative case series METHODS: Medical records of patients diagnosed with congenital aniridia were retrospectively reviewed. Age, gender, ethnicity, follow-up time, AAK stage, non-corneal abnormalities, ocular surgeries, and complications were recorded. The visual acuity equivalent (VAE), approximate Early Treatment Diabetic Retinopathy Study (appETDRS) letter score, was calculated using recorded Snellen visual acuities. Ninety-two eyes of 47 patients (31 females) with mean age of 48.0±18.0 years, and mean follow-up of 78.6±42.2 months were included. At the initial visit, 12 eyes (13%) were classified as stage I AAK, 33 eyes (35.9%) stage II, 25 eyes (27.2%) stage III, 17 eyes (18.5%) stage IV and 5 eyes (5.4%) stage V. Limbal stem cell transplantation (LSCT) and Boston Keratoprosthesis (KPro) were frequently performed on eyes with stages III-V. These advanced corneal surgeries significantly improved the median (95% CI) of calculated appETDRS scores from 2(0-20) to 26(15-41) (Snellen, 20/20000 to 20/300, P=0.0004). Patients with earlier stages (I-II) of AAK were managed medically and had stable visual acuity through their final visits (appETDRS, 26(20-35) to 35(26-35), Snellen, 20/300 to 20/200,P>0.05). The appETDRS VAE was significantly improved from 20(0-35) to 30(20-55), Snellen 20/400 to 20/250, following LSCT (P=0.021) and from 2(0-20) to 2(0-41) after KPro, same 20/20000 Snellen VAE, but with improved 95% CI after follow-up (P=0.019). With proper characterization and staging of AAK, individualized medical and advanced surgical interventions preserves and improves visual acuity.